Clinical Trials

84 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07458113 2026-03-09

BERLIN

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT07458204 2026-03-09

EPPIL

760 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT07276880 2026-03-03

P-RAD(+)TN-DCT

32 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

26 enrolled

Triple Negative Breast Neoplasms

NCT07419880 2026-02-19

RECLAIM

46 enrolled

Triple Negative Breast Neoplasms

NCT05741164 2026-02-17

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

37 enrolled

Triple Negative Breast Neoplasms

NCT07217990 2026-02-17

NoCUT-BC

84 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06224673 2026-02-13

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

36 enrolled

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

30 enrolled

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07407517 2026-02-12

POLARIS

904 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07340541 2026-02-09

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07283692 2026-02-03

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

46 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07378306 2026-01-30

FACT-TN

80 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07357948 2026-01-22

WISH-OMICHIR

150 enrolled

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07321015 2026-01-06

Fzp-MA-TNBC

72 enrolled

Triple Negative Breast Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

40 enrolled

Triple Negative Breast Neoplasms

NCT07271992 2025-12-09

TREND-02

30 enrolled

Triple Negative Breast Neoplasms

NCT07244874 2025-11-24

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

41 enrolled

Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

765 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05806385 2025-09-09

LOGIC

36 enrolled

Triple Negative Breast Neoplasms

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

12 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

150 enrolled

Triple Negative Breast Neoplasms

NCT07153965 2025-09-04

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

47 enrolled

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

260 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

59 enrolled

Triple Negative Breast Neoplasms

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

125 enrolled

Triple Negative Breast Neoplasms

NCT07007780 2025-07-29

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

35 enrolled

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06195618 2025-06-25

TEBICA003 TNBC

8 enrolled

Triple Negative Breast Neoplasms

NCT07011823 2025-06-10

KEY-MELT

Triple Negative Breast Neoplasms

NCT07005583 2025-06-05

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

46 enrolled

Triple Negative Breast Neoplasms

NCT06975644 2025-05-22

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

55 enrolled

Triple Negative Breast Neoplasms

NCT06977542 2025-05-18

Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

53 enrolled

Phase 2/3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06910072 2025-04-04

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

32 enrolled

Triple Negative Breast Neoplasms

NCT06691594 2025-02-20

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Triple Negative Breast Neoplasms

NCT06831955 2025-02-18

LESLIE

356 enrolled

Triple Negative Breast Neoplasms

NCT05821686 2025-02-12

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

10 enrolled

Triple Negative Breast Neoplasms

NCT06798506 2025-01-29

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

300 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06787339 2025-01-22

Calorite

198 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

40 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06396754 2024-10-02

AIDOBE

50 enrolled

Triple Negative Breast Neoplasms

NCT06497322 2024-07-11

Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment

60 enrolled

Breast Neoplasms, Motor Activity, Triple Negative Breast Neoplasms

NCT06448169 2024-06-07

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

200 enrolled

Hypersensitivity, Triple Negative Breast Neoplasms

NCT06418139 2024-05-16

PEMCLOCK

450 enrolled

Triple Negative Breast Neoplasms

NCT06407310 2024-05-09

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

25 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER